Important: MadeMed is a telehealth platform that facilitates access to prescription medications. It does not provide direct medical care. All prescribing decisions are made by licensed clinicians affiliated with Xpedicare, LLC, an independent medical group. Compounded medications dispensed through this platform are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This review is for informational and educational purposes only. Consult your healthcare provider before starting any prescription treatment.
The compounded GLP-1 telehealth market has expanded to dozens of platforms in the last two years, and most of what you'll find when you search for reviews falls into one of two failure modes: promotional content that reads like a sales page, or vague skepticism that doesn't tell you anything specific. This review does neither. We examined MadeMed's public-facing website, its Terms of Use, third-party verification sources, and the broader regulatory environment around compounded semaglutide to give you a research-level breakdown of what this platform actually offers — and what you need to verify before enrolling.
What Is MadeMed?
MadeMed is an online telehealth platform operated by IDL Health LLC, headquartered in Houston, Texas. The platform connects patients with licensed medical providers affiliated with Xpedicare, LLC, an independent medical group that is solely responsible for clinical services and all prescribing decisions. MadeMed holds LegitScript certification, an independent verification standard that evaluates online healthcare companies for legal compliance, safety, and transparency. Medication is dispensed through AbsoluteRx, a licensed pharmacy partner.
The platform operates across four clinical categories: GLP-1 weight loss programs, men's sexual health, peptide therapy, and NAD+ therapy. For most prospective patients, the GLP-1 weight-loss programs are the primary focus—and that's where the majority of this review is concentrated.
MadeMed GLP-1 Programs: What the Platform Offers
MadeMed offers four GLP-1 medication formats. Injectable semaglutide and injectable tirzepatide are the traditional subcutaneous injection options administered once weekly. Oral semaglutide and oral tirzepatide are compounded sublingual tablet formulations that dissolve under the tongue — a needle-free alternative that has grown significantly in market share among telehealth GLP-1 platforms in 2025 and 2026.
It's worth being specific about what “oral semaglutide” means in this context. The compounded sublingual tablets available through MadeMed and most telehealth platforms differ from the FDA-approved oral semaglutide products that have reached the market — specifically Rybelsus (the original oral tablet) and the oral Wegovy formulation launched in late 2025. Compounded sublingual semaglutide is not an FDA-approved finished drug and has not been evaluated in phase 3 human trials for efficacy or bioavailability under the same conditions as the approved oral formulations. For a more detailed breakdown of the oral format landscape, see our comparison of oral GLP-1 telehealth programs.
MadeMed Pricing: What the Published Numbers Actually Mean
Based on publicly available information as of May 2026, MadeMed's oral semaglutide program starts at $99 per month at the lowest dose tier. Pricing increases as doses are titrated upward throughout treatment. NAD+ nasal spray is listed at up to $269 per month at higher tiers. An optional MadeMed Club membership, priced at $149 per year, provides a $10 monthly discount across the platform's programs.
A few pricing realities worth understanding before you commit. First, the starting price is almost never the price you'll actually pay at a therapeutic maintenance dose. GLP-1 programs begin at the lowest titration dose — typically 0.25mg for semaglutide — and increase over months based on individual response and tolerability. The per-month cost typically increases with dose. Second, subscription billing is automatic. MadeMed's Terms of Use state that services are offered on a recurring subscription basis and that the platform does not offer prorated refunds. Cancellation is available via email to support@mademed.com or through the account portal and takes effect at the end of the current billing period. Read those terms before you enter payment information.
For context on how MadeMed's pricing compares to other compounded GLP-1 platforms in the current market, see our analysis of the MEDVi GLP-1 program, which starts at $179 per month for injectable semaglutide, and our review of SynergyRx GLP-1, which offers oral dissolving tablet options starting at $299 per month for semaglutide. At its published starting price, MadeMed's oral semaglutide option sits at the lower end of the compounded telehealth market.
Regulatory Context: Compounded Medications and the 2025-2026 Enforcement Environment
This section matters more in 2026 than it would have two years ago, and anyone considering a compounded GLP-1 program should understand it clearly.
Compounded medications are patient-specific formulations prepared by licensed compounding pharmacies. They are legal and widely prescribed, but they are not FDA-approved finished drugs. The FDA does not evaluate compounded medications for safety, efficacy, or quality control before they are dispensed. MadeMed's Terms of Use state this explicitly: “Compounded drugs are not approved by the Food and Drug Administration (FDA) and are not evaluated for safety or efficacy.” That level of disclosure is legally required and factually accurate.
The broader regulatory environment has shifted since mid-2025. The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in December 2024. When a branded drug is no longer on the FDA shortage list, the legal authority for compounding pharmacies to produce bulk copies of that drug significantly narrows. The FDA has escalated enforcement against compounded GLP-1 marketing since September 2025, issuing warning letters to multiple telehealth platforms for misbranding violations. In March 2026, Hims & Hers reached a settlement with Novo Nordisk and announced it would stop marketing compounded GLP-1 medications, signaling a major pivot among large-scale telehealth players.
None of this means compounded semaglutide or tirzepatide is currently unavailable or illegal. Patient-specific compounding through 503A pharmacies remains a legal pathway when a prescribing clinician determines a compounded formulation is medically necessary for a specific patient. But the landscape is actively changing, and platforms operating in this space — including MadeMed — face ongoing regulatory scrutiny. Prospective patients should verify current program availability, pricing, and medication sourcing directly on mademed.com before enrolling, as conditions may have changed since this review was written.
The Weight Loss Outcome Claim: What the Research Actually Supports
MadeMed cites an average body weight loss of 15 to 20 percent on its platform. This figure deserves precise context. The 15 to 20 percent body weight reduction range reflects outcomes reported in large-scale clinical trials of FDA-approved semaglutide at the 2.4mg weekly dose — specifically the STEP trial program, which studied brand-name injectable Wegovy in adults with obesity alongside lifestyle intervention. Those trials involved FDA-approved finished drug formulations, conducted in controlled conditions, and enrolled populations meeting specific eligibility criteria.
That clinical literature does not establish that MadeMed's compounded semaglutide products — which are not FDA-approved and have not been evaluated in equivalent trials — will produce the same outcomes. Individual weight-loss results depend on dose, adherence, individual physiology, lifestyle factors, starting weight, and other variables. No telehealth platform can guarantee specific outcomes from compounded GLP-1 therapy, and none should. The research supports that semaglutide, when prescribed appropriately and used alongside lifestyle modification under medical supervision, has demonstrated meaningful weight reduction in certain patient populations. Whether any individual qualifies for and responds to GLP-1 therapy is a clinical determination — one made by the licensed providers within Xpedicare, LLC, not by MadeMed.
The MadeMed Intake and Prescribing Process
The enrollment process follows the standard telehealth model used across the compounded GLP-1 market. Prospective patients complete an online medical intake form covering health history, current medications, and weight goals. That information is reviewed by a licensed clinician affiliated with Xpedicare, LLC. The Terms of Use make clear that there is no guarantee a prescription will be written — the prescribing decision is entirely at the clinician's discretion based on their professional judgment. MadeMed's Terms of Use also specify that providers do not prescribe DEA-controlled substances.
If a prescription is issued, it is transmitted to AbsoluteRx, MadeMed's licensed pharmacy partner, for fulfillment and direct shipment. Services run on a subscription billing cycle — either 30 or 90 days, depending on the plan selected.
MadeMed's Other Programs: Men's Health, Peptide Therapy, and NAD+
Beyond GLP-1, MadeMed offers a tadalafil-based men's sexual health troche that combines tadalafil with PT-141 and oxytocin. For peptide therapy, the platform offers both injectable and oral sermorelin. Sermorelin is a peptide that may support growth hormone release in certain individuals under medical supervision; it is not approved for anti-aging or general wellness use and requires appropriate clinical evaluation before prescribing. NAD+ therapy is available as both an injectable and a nasal spray.
For a focused review of MadeMed's sermorelin and peptide therapy programs specifically, see our dedicated breakdown: MadeMed Sermorelin and Peptide Therapy: What Patients Should Know.
Is MadeMed Legitimate? What Independent Verification Tells Us
Based on available information: yes, MadeMed is a real, operating telehealth platform. LegitScript certification indicates the platform has met independent standards for legal compliance and safety in online healthcare operations. The three-entity structure — MadeMed as the platform operator, Xpedicare, LLC as the independent medical group providing clinical services, and AbsoluteRx as the pharmacy partner — is consistent with how compliant telehealth platforms structure the separation between non-clinical services and medical care.
The more useful question for prospective patients is not “is it legitimate?” but “is it the right fit for me?” That depends on your state's availability, your medical history, whether compounded GLP-1 therapy is appropriate for your specific situation, the current regulatory status of the programs you're considering, and how MadeMed's pricing compares at your expected maintenance dose. The answer to those questions requires a conversation with a licensed clinician — one who has reviewed your actual health history. For additional context on how MadeMed compares to other platforms with similar care models, see our reviews of Direct Meds GLP-1 and TeleHealth Med.
What to Verify Before Enrolling with MadeMed
Confirm your state is included in MadeMed's current service area — approximately 40 states as of this writing, but subject to change. Verify current pricing for the specific medication and dose tier you're likely to reach at maintenance, not just the starter price. Read the subscription and cancellation terms in MadeMed's Terms of Use before entering payment information. Ask your prescribing clinician about the pharmacy sourcing for your specific formulation and request a Certificate of Analysis if you want to verify medication quality and ingredient testing. If you are currently taking any medications, including thyroid medications or GLP-1 pathway medications, discuss potential contraindications with a qualified provider before starting. And verify current program availability and pricing directly on mademed.com, as the compounded GLP-1 regulatory environment continues to evolve and information in third-party reviews — including this one — may not reflect the most current program terms.
Frequently Asked Questions
Is MadeMed a legitimate telehealth platform?
MadeMed is operated by IDL Health LLC and holds LegitScript certification. Medical services are provided by Xpedicare, LLC, an independent medical group. All prescribing decisions are made by licensed clinicians — not MadeMed — and medication is dispensed through AbsoluteRx, a licensed pharmacy partner.
How much does MadeMed cost per month?
Published pricing starts at $99 per month for oral semaglutide. NAD+ nasal spray is listed up to $269 per month. An optional MadeMed Club membership at $149 per year provides a $10 monthly discount. Final pricing depends on medication type, dose, and plan structure and should be verified directly on mademed.com before enrollment.
Are MadeMed's GLP-1 medications FDA-approved?
No. MadeMed's Terms of Use state explicitly that compounded medications dispensed through the platform are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This is the regulatory standard for all compounded drugs in the United States.
What states is MadeMed available in?
MadeMed reports availability in approximately 40 states. Certain medications or clinical services may not be available in all states due to state-specific restrictions. Prospective patients should verify their state's availability directly on the platform before completing an intake form.
What medications does MadeMed offer?
MadeMed offers injectable and oral compounded semaglutide, injectable and oral compounded tirzepatide, a tadalafil-based men's wellness troche, injectable and oral sermorelin for peptide therapy, and NAD+ in both injectable and nasal spray formats.